Aspergillosis Treatment Market Opportunity Analysis, 2018-2026
Chronic pulmonary aspergillosis is rare pulmonary disease, which increases symptoms of respiratory disorders such as asthma. According to a study published by European Respiratory Society (ERS) publications, in 2015, CPA is estimated to affect nearly 240,000 people in Europe. The most common form of CPA is Chronic Cavitary Pulmonary Aspergillosis (CCPA), which if left untreated can develop chronic fibrosing pulmonary aspergillosis. According to a statistics published by Centers for Disease Control and prevention, (CDC) an estimated 10% of individuals with asthma or cystic fibrosis experience an allergic reaction to aspergillus. ABPA is estimated to affect 2-15% of patients with cystic fibrosis and around 2% of all asthma patients.
Increasing prevalence of Aspergillosis and favorable government regulations are the major factors driving growth of the Aspergillosis treatment market. According to a study published in Journal of Fungi 2016, CPA is estimated to affect nearly three million people globally making it major health problem resulting in mortality and morbidity. Aspergillosis infection can be treated with antifungal and corticosteroids drugs. Corticosteroid drugs are prescribed for allergic bronchopulmonary aspergillosis treatment.
Comments
Post a Comment